Mr Daniel Croagh
MBBS, PhD, FRACS
Mr Daniel Croagh is a Hepatobiliary Surgeon and Interventional Endoscopist. During his surgical training, he undertook a PhD at the Peter MacCallum Cancer Centre in cell biology with a focus on oesophageal stem cells and the development of in-vivo models to investigate Barrett’s oesophagus.
He then completed his training in HPB surgery including a two-year fellowship at the Queen Elizabeth Hospital in Birmingham, UK. After completing his PhD in 2005, he has maintained a strong interest in research whilst completing his training in pancreatic surgery and interventional endoscopy. He is recognised for his training in endoscopic ultrasound and ERCP by the Conjoint Committee for Recognition of Training in Endoscopy.
In the last 10 years, his responsibilities have included contributing to the development of the hepatobiliary surgical service at Monash Health, which caters for a patient catchment of 1.3 million people in the south-east of Melbourne, along with promoting clinical research in the Upper GI and HPB unit. He has devoted a large amount of time to the provision of patient care, staff training and change of management within surgery.
The number of pancreatic resections has increased 4-fold since his appointment in 2011. He has spent approximately 10% of his time on translational research during this period and this has been focused on the clinical trials and the development of EUS-FNA for the molecular profiling of pancreatic cancer to guide patient targeted therapies.
Education and Experience
MBBS (Hons) — University of Melbourne 1997
PhD — University of Melbourne 2007
Fellow of the Royal Australasian Colleague of Surgeons (FRACS) — 2007
Current Research Interests
Clinical trials and the development of EUS FNA for the molecular profiling of pancreatic cancer to guide patient targeted therapies
Publications
Partelli S, Ramage JK, Massironi S, Zerbi A, Kim HB, Niccoli P, Panzuto F, Landoni L, Tomazic A, Ibrahim T, Kaltsas G, Bertani E, Sauvanet A, Segelov E, Caplin M, Coppa J, Armstrong T, Weickert MO, Butturini G, Staettner S, Boesch F, Cives M, Moulton CA, He J, Selberherr A, Twito O, Castaldi A, De Angelis CG, Gaujoux S, Almeamar H, Frilling A, Vigia E, Wilson C, Muffatti F, Srirajaskanthan R, Invernizzi P, Lania A, Kwon W, Ewald J, Rinzivillo M, Nessi C, Smid LM, Gardini A, Tsoli M, Picardi EE, Hentic O, Croagh D, Toumpanakis C, Citterio D, Ramsey E, Mosterman B, Regi P, Gasteiger S, Rossi RE, Smiroldo V, Jang JY, Falconi M. Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study. Front Med (Lausanne). 2020 Dec 23;7:598438
Maharaj AD, Evans SM, Zalcberg JR, Ioannou LJ, Graco M, Croagh D, Pilgrim CHC, Dodson T, Goldstein D, Philip J, Kench JG, Merrett ND, Neale RE, White K, Evans P, Leong T, Green SE. Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework. PLoS One. 2020 Dec 17;15(12):e0243312.
Holokai L, Chakrabarti J, Lundy J, Croagh D, Adhikary P, Richards SS, Woodson C, Steele N, Kuester R, Scott A, Khreiss M, Frankel T, Merchant J, Jenkins BJ, Wang J, Shroff RT, Ahmad SA, Zavros Y. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2020 Dec 17;12(12):3816.
Pilgrim CHC, Te Marvelde L, Stuart E, Croagh D, Deutscher D, Nikfarjam M, Lee B, Christophi C. Population-based analysis of treatment patterns and outcomes for pancreas cancer in Victoria. ANZ J Surg. 2020 Sep;90(9):1677-1682.
Barbour AP, Samra JS, Haghighi KS, et al. The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. Ann Surg Oncol. 2020;10.1245/s10434-020-08205-2.
Lau DK, Mouradov D, Wasenang W, et al. Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets. iScience. 2019;21:624–637.
Maharaj AD, Samoborec S, Evans SM, et al. Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review [published online ahead of print, 2019 Oct 18]. HPB (Oxford). 2019;S1365-182X(19)30711-7
Freckelton J, Croagh D, Holt DQ, et al. Body Composition Adjusted Dosing of Gemcitabine-Nab-Paclitaxel in Pancreatic Cancer Does Not Predict Toxicity Compared to Body Surface Area Dosing. Nutr Cancer. 2019;71(4):624–628.
Maharaj AD, Ioannou L, Croagh D, et al. Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. HPB (Oxford). 2019;21(4):444–455.
Berry W, Lundy J, Croagh D, Jenkins BJ. Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer. Cancers (Basel). 2018;10(2):35.
Berry W, Croagh D. Utility of Endoscopic Ultrasound-Guided Fine-Needle Aspiration for Preclinical Evaluation of Therapies in Cancer. Methods Mol Biol. 2018;1725:31–40.
Segelov E, Lordick F, Goldstein D, Chantrill LA, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price TJ. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther. 2017 Oct;17(10):951-964.
Berry W, Algar E, Kumar B, Desmond C, Swan M, Jenkins BJ, Croagh D. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors. Int J Cancer. 2017 May 15;140(10):2331-2343.
Poh BR, Ho SP, Sritharan M, Yeong CC, Swan MP, Devonshire DA, Cashin PA, Croagh DG. Randomized clinical trial of intraoperative endoscopic retrograde cholangiopancreatography versus laparoscopic bile duct exploration in patients with choledocholithiasis. Br J Surg. 2016 Aug;103(9):1117-24.
Teaching Roles
Lecturer — Department of Surgery, Monash University
Public Hospital Appointments
Hepatobiliary and pancreatic surgeon and interventional endoscopist:
Monash Health
Epworth Healthcare
Professional Associations
Clinical lead for the Pancreatic Module of the UGI Cancer Registry (2016 to present)
Honorary Associate, Hudson Institute (2018 to present)
Board member for the Conjoint Committee for the Recognition of Training in Endoscopy (2019 to present)
Member of the Scientific Advisory Committee for the AGITG (2019 to present)
Steering group member – VCCC program 2 - Drive translation of cancer biology to 21st century personalised cancer care, prioritising new technologies and low survival cancers. (2021 to present)
Qualifications
MBBS
PhD
FRACS